wait game continu ahead data rich
invest summari reiter neutral rate
price target view compani novel pipelin potenti blockbust
although safeti concern rais phase data lack signific
catalyst keep us sidelin could construct
stock compani abl advanc early-stag novel drug show posit
efficaci safeti data believ concern around phase creatin
kinas ck albumin data may turn overdon howev would like
see data move sidelin data readout
potenti blockbust opportun posit investor
stock may still well reward prove choic remain sidelin
conserv
takeaway quarter commenc two phase clinic
studi gmg hdfn top-line result anticip
respect compani recent capit rais fund
proof concept readout novemb result
phase clinic trial healthi volunt publish
clinic pharmacolog journal remain track
announc third indic around januari
compani announc dose first subject phase clinic trial
itp data expect novemb announc agreement
nc allow launch market format
novemb novemb notifi chen termin
biosimilar candid except biosimilar eylea compani
cash cash equival hand
 report ep factset consensu
higher estim updat financi model
increas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf ev/ebitda valuat arriv price target
momenta one commerci product glatopa repres signific portion compani
revenu face increas competit could affect demand price glatopa
glatopa revenu estim could drive stock valuat current
pipelin delay failur and/or higher forecast competit gener brand
quicker forecast could provid upsid risk valuat rate
drug price may face pressur downsid risk entir industri custom
consolid creat greater leverag buy consortium extract price
concess compani
competit momenta product could neg effect momenta market share
price could make hard moment meet financi target
momenta believ suffici cash fund oper howev compani need
rais addit capit bring pipelin market partnership non-dilut
fund sourc could drive upsid current valuat rate
even momenta pipelin meet endpoint clinic trial guarante
compani product approv fda subsequ commerci
momenta follow strategi partner number product momenta thu reliant
partner meaning part futur revenu pipelin advanc
momenta undergon strateg review guarante decis taken
review result plan
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull bear case
scenario base analysi estim likelihood stock worth next month
exhibit bull bear base case scenario analysi
momentasourc cantor fitzgerald research compani caseglatopa revenu exce forecastsuccess advanc novel pipelin across three product captur market shareexpand product scenario caseglatopa revenu line forecastadv novel pipelineexpand product scenario caseglatopa revenu forecastnovel pipelin experi setback delaysdo expand product offer scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot higher revenu recogn relat collabor agreement terminationcogs- nm- nm- gross decreas spend biosimilar programsoth oper oper non oper pre-tax taxes- nm- nm- tax net averag cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom phase open label extens studi humira biosimilar submit eu filingaround third clinic studi eylea biosimilar advanc phase toward completionbi end phase humira biosimilar identifi collabor concept result clinic data phase studi humira biosimilar eu humira biosimilar submit label extens result concept result histori studi result registr studi phase studi studi result humira biosimilar humira biosimilar potenti launch eylea biosimilar eylea biosimilar market format potenti file studi result studi result file file launch one autoimmun indicationssourc cantor fitzgerald research compani report exhibit incom statement analysi
million compound-annual-growth-rate year end decemb oper share chang yoytot ratenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtaxesnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet cantor fitzgerald research compani report exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb develop collabor chang yoyproduct collabor othernmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtot cantor fitzgerald research compani report exhibit annual sale analysi
develop collabor cantor fitzgerald research compani reportsyear end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas net proce sale acquisit net cash acquired- other- net cash use invest flow financ activ repay issuanc long term debt- proce issuanc other- net cash use provid financ net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt inventories- current total current plant properti identifi goodwill- total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling interest- total liabil stockhold sourc cantor fitzgerald research compani report februari
momenta biotech compani focus develop complex gener product biosimilar novel therapi autoimmun diseas
momenta success develop first gener lovenox enoxaparin sodium inject first gener copaxon gener
version copaxon momenta current develop effort leverag expertis bring complex gener
market focus develop biosimilar well novel drug therapi use compani complex analysi platform biolog
protein engin capabl momenta partner number program sandoz market gener copaxon product
glatopa compani partner biosimilar program behr recombin fc multim
